Lizzi Collinge

It is a pleasure to serve here today under your chairship, Ms Allin-Khan. I thank the hon. Member for Chesham and Amersham (Sarah Green) for securing this important debate. I am going to focus on sodium valproate, which was prescribed for decades without proper warnings about the effect on unborn children. As a result, those children were harmed and, despite multiple Government-commissioned reports, families are still waiting for accountability and redress. Two years on from the Hughes report, that delay can no longer be justified. Sodium valproate is a medicine used to treat epilepsy and bipolar disorder. It is a very effective medicine for many but, if taken while pregnant, it can cause serious harm. Those harms include major physical birth defects, developmental delays, learning disabilities and a significantly increased risk of autism. Many of the children affected will need lifelong care. For years, despite those risks being known, women and prescribers were not given clear or adequate information about them. Even after the effects were more widely known, prescriptions continued without proper safeguards in place. At least 7,000 children have been affected by this medicine since it came on to the market in 1973, but the real number is quite likely very much higher because of the lack of awareness around foetal valproate spectrum disorder. My constituent Nicola was one of the many women affected. Her children were profoundly harmed by exposure during pregnancy. Like so many others, Nicola trusted her doctor and followed proper medical advice. She was badly let down. She has explained to me just how immense the impact has been on her and her children and, of course, what a difference compensation would make to her kids’ lives.